Clinical Trials Directory

Trials / Unknown

UnknownNCT01473459

Comparison Between Two Fertility Protocols in Obese Polycystic Ovary Syndrome Patients

Comparison Between Two Fertility Protocols in Obese Polycystic Ovary Syndrome

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Hillel Yaffe Medical Center · Other Government
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to compare two fertility protocols in obese women with Polycystic Ovarian Syndrome who are candidates for In Vitro Fertilization (IVF). These protocols carry less risk of ovarian hyperstimulation syndrome which these women may experience.

Detailed description

The purpose of this study is to compare two fertility protocols in obese women with Polycystic Ovarian Syndrome who are candidates for In Vitro Fertilization (IVF). These protocols carry less risk of ovarian hyperstimulation syndrome which these women may experience.The patients in the IVM group will not be exposeD to gonadotropin treatment for controlled ovarian hyperstimulation. In the antagonist group we will use GnRH agonist to induce ovulation which may reduce the risk for ovarian hyperstimulation.

Conditions

Interventions

TypeNameDescription
PROCEDUREIVM (In Vitro Maturation) TreatmentThere will be no gonadotropin stimulation. There will be ovum pickup from antral follicles of immature oocyte which will be matured in the lab and fertilized by intracytoplasmic sperm injection (ICSI). Embryo transfer will take place on days 2 or 3.
PROCEDUREIVF (In Vitro Fertilization) Antagonist ProtocolThe first stage of the treatment will be stimulation with gonadotropins. Next GNRH Antagonist will be added. Ovulation induction will be performed with GNRH agonist. After ovulation there will be ovum pickup and fertilization in the lab. Embryo transfer will take place on days 2 or 3.

Timeline

Start date
2012-04-01
Primary completion
2013-01-01
Completion
2013-01-01
First posted
2011-11-17
Last updated
2012-04-26

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT01473459. Inclusion in this directory is not an endorsement.